St.James Hospital

Dublin Dublin 8

7 studies enrolling now · 33 studies all time

What they study most

1st Line NSCLC, Advanced Solid Tumor, Amyotrophic Lateral Sclerosis, Anemia, BPH With Symptomatic Lower Urinary Tract Symptoms, Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited, Breast Cancer, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carotid Stenosis, Cholangiocarcinoma

Studies at this site

• A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Recruiting now
• Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression — Recruiting now
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer — Recruiting now
• Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers — Recruiting now
• Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer — Recruiting now
• BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours — Recruiting now
• Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma — Recruiting now
• FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS) — Running, not enrolling
• An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions — Running, not enrolling
• ProVIDE II Bridging Study — Running, not enrolling
• A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy — Running, not enrolling
• Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma — Running, not enrolling
• Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression — Completed
• A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Completed
• A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer — Completed
• Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC — Completed
• Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer — Running, not enrolling
• Carotid Endarterectomy Versus Carotid Artery Stenting in Asymptomatic Patients — Status unconfirmed
• A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2) — Completed
• Entyvio (Vedolizumab) Long Term Safety Study — Completed
• Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer — Completed
• Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma — Completed
• AAV Gene Therapy Screening/Observational Protocol (ECLIPSE) — Completed
• A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer — Completed
• Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients — Stopped early
• A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting — Completed
• A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer — Stopped early
• ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer — Completed
• Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer — Stopped early
• Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer — Completed
• A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer — Completed
• A Pharmacogenomic Exploration of Lacosamide Response — Status unconfirmed
• A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study) — Completed